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Abstract
Background: The incidence of cryptococcal meningitis (CM) and tuberculous meningitis (TBM) have gradually
increased in recent years. These two types of meningitis are easily misdiagnosed which leads to a poor prognosis.
In this study we compared differences of clinical features and prognostic factors in non-HIV adults with CM and
TBM.
Methods: We retrospectively reviewed the medical records of CM and TBM patients from January 2008 to
December 2015 in our university hospital in China. The data included demographic characteristics, laboratory
results, imaging findings, clinical outcomes.
Results: A total of 126 CM and 105 TBM patients were included. CM patients were more likely to present with
headache, abnormal vision and hearing, and they might be less prone to fever and cough than TBM patients
(P < 0.05). Higher percentage of CM patients presented with cerebral ischemia/infarction and demyelination in brain
MRI than TBM patients (P < 0.05). CM patients had lower counts of WBC in CSF, lower total protein in CSF and
serum CD4/CD8 ratio than TBM patients (P < 0.05). After three months of treatment, CM group have worse
outcome than TBM group (P < 0.05). Multivariate analysis showed that age more than 60y (OR = 4.981, 95% CI: 1.
955–12.692, P = 0.001), altered mentation (OR = 5.054, 95% CI: 1.592–16.046, P = 0.006), CD4/CD8 ratios < 1 (OR = 8.
782, 95% CI: 2.436–31.661, P = 0.001) and CSF CrAg ≥ 1:1024 (OR = 4.853, 95% CI: 1.377–17.098, P = 0.014) were
independent risk factors for poor prognosis for CM patients. For TBM patients, hydrocephalus (OR = 7.290, 95% CI: 1.
630–32.606, P = 0.009) and no less than three underlying diseases (OR = 6.899, 95% CI: 1.766–26.949, P = 0.005) were
independent risk factors, headache was a protective factor of prognosis.
Conclusions: Our study provided some helpful clues in the differential diagnosis of non-HIV patients with CM or
TBM and identified some risk factors for the poor prognosis of these two meningitis which could help to improve
the treatment outcome. Further studies are worth to be done.
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Background
Many organisms such as meningococcus, Mycobacterium
tuberculosis and Cryptococcus neoformans can result in
meningitis. With increasing use of immune suppressive
medication use in rheumatologic conditions, oncology,
and organ transplantation, the incidence of Cryptococcal
meningitis (CM) and tuberculous meningitis (TBM) are
rising [1, 2].
CM and TBM are the two most common types of
chronic infectious meningitis, especially in developing
countries, and may have similar clinical manifestations
and cerebrospinal fluid (CSF) findings [3, 4]. Although
mortality has decreased significantly in recent years, with
the advent of new antimicrobial drugs, diagnostic tech-
niques and treatment strategies, it remains high [3, 5–7].
CM and TBM are easily misdiagnosed due to vague clin-
ical syndromes associated with these conditions [3, 6].
Delay of diagnosis and treatment are directly related to a
poor prognosis [3, 8]. Early diagnosis CM and TBM, espe-
cially TBM, remain challenges for clinicians.
CM and TBM are common in human immunodefi-
ciency virus (HIV) infected patients, but they are also
seen in patients with other forms of immunosuppression
and apparently immunocompetent individuals [9]. Some
studies have sought to identify clinical features in order
to distinguish TBM from CM in human HIV infected
patients [10, 11]. Data on how to identify CM and TBM
according to clinical profiles in HIV negative patients
are scarce. In this retrospective study, we aimed to com-
pare the demographic features, clinical presentations,
laboratory data, radiographic findings, therapeutic
outcomes and prognostic factors of HIV negative TBM
and CM patients who were admitted to a university
hospital from 2008 to 2015 in China.
Methods
Study population
The retrospective study was conducted between January
2008 and December 2015, in West China Hospital,
Sichuan University, China (a 4,300-bed academic tertiary
care hospital). Patients aged 14 years or older with con-
firmed diagnosis of CM or clinical or confirmed diagno-
sis of TBM were included. Exclusion criteria were age
under 14 years, HIV positive with infected, pregnant
mothers, CM combined with TBM, and cases lacking
follow-up for anti-tuberculosis or anti-fungal treatment.
The diagnosis of CM and TBM were made by clinical
and laboratory findings. Symptoms and signs of menin-
gitis including one or more of the following: headache,
vomiting, fever, neck stiffness, convulsions, focal neuro-
logical deficits, altered mentation. Laboratory assess-
ments for CM included CSF culture, CSF India ink
testing, and CSF cryptococcal antigen testing (CrAg).
Patients with TBM included definite TBM and clinical
diagnosis of TBM. The diagnostic criteria of definite
TBM was clinical findings plus one or more of the
following: acid-fast bacilli seen in the CSF, M. tubercu-
losis cultured from the CSF, or a CSF positive commer-
cial nucleic acid amplification test. The clinical diagnosis
of TBM based on the clinical algorithm [12], which
modified according to Marais’ definitions [13]. All en-
rolled patients were divided into CM and TBM groups.
Altered mentation in CM and TBM refers to general
changes in brain function, such as confusion, amnesia, loss
of alertness, loss of orientation, defects in judgment and
unusual behavior. Which were confirmed by psychiatrists.
Laboratory studies
Laboratory tests such as complete blood counts, blood
biochemistry, interferon gamma release assays (IGRAs),
peripheral blood T lymphocyte subset measurements
and HIV test were done at the department of laboratory
medicine of our hospital. Lumbar puncture (LP) and tu-
berculin skin test (TST) of suspected CM or TBM cases
were performed before initial treatment. CSF was sent
for WBC, glucose, protein, chloride, India ink stain, CSF
cryptococcal antigen titers, TB smear, TB PCR, fungal
and M. tuberculosis cultures. These tests were done at
the discretion of the treating physicians. Fluorescence
quantitative PCR was used to detect TB DNA in CSF.
The rapid liquid culture mediums were used to detect
M. Tuberculosis. Fungal culture of CSF was performed
on Sabouraud dextrose agar (SDA) and incubated at 30°C
to obtain cryptococcus isolates. The CSF cryptococcal
antigen titers were determined by Latex Cryptococcal
Antigen Detection System (Immuno-Mycologics, Inc.,
Norman, USA). The test utilizes latex particles coated
with anti-cryptococcal antibody, which will reacts with the
cryptococcal capsular polysaccharide antigen causing a
visible agglutination. Brain magnetic resonance imaging
(MRI) or computed tomography (CT) examinations and
chest CT were performed at the discretion of the
physicians.
Treatment strategies
All the patients received treatments after they got the
diagnoses. Time of diagnosis was the time from onset of
symptoms to treatment. HIV negative CM patients were
treated with amphotericin B (0.7–1 mg/kg/d), 5-
flucytosine (100 mg/kg/d) with or without fluconazole
(800 mg/day)/voriconazole (loading dose, 6mg/kg/12h,
maintenance dose, 4mg/kg/12h) for 6–12 weeks of in-
duction therapy, and then fluconazole (400 mg/day) for
8 weeks of consolidation therapy, fluconazole (200 mg/
day) for more than 6 months of maintenance therapy
according to the guidelines for the management of
cryptococcal disease and our experiences [5, 14]. Only
three patients with CM received voriconazole. Because
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amphotericin B was contraindicated in some patients
with kidney disease or renal inadequacy emerged after
use of amphotericin B in another patient. Continuous
lumbar drainage subarachnoid were applied to the CM
patients with persistent high intracranial pressure. The
treatment regimen for TBM patients who had not been
treated with chemotherapy consisted of three months of
isoniazide (INH), rifampin (RIF), pyrazinamide (PZA),
and streptomycin (SM)/ethambutol (EMB), followed by
INH and RIF [15, 16]. The total treatment course was at
least 12 month. Second-line treatment regimens were
given after failure to first-line TB chemotherapy accord-
ing to the guideline and patients’ situation [15, 16].
Data collection
We retrospectively reviewed the medical records of
patients involved in this study. We obtained demo-
graphic characteristics, underlying diseases, use of
steroids, symptoms and signs on admission, duration of
initial symptoms to diagnosis or treatment, laboratory
data, brain MRI /CT findings and clinical outcomes. The
clinical outcomes were evaluated after three-month of
treatment. Risk factors for the prediction of poor of HIV
negative CM and TBM patients were also evaluated. All
data were verified by two authors independently.
Ethical considerations
The study was approved by the Ethics Committee of
West China Hospital, Sichuan University, which waived
the need for informed consent because all the data used
in this study were routinely obtained and no additional
procedures were carried out.
Statistical analysis
Statistical analyses were performed using SPSS version
17.0 software package (SPSS Inc., Chicago, USA). The
Shapiro-Wilk normality test was used for testing nor-
mality for all quantitative variables. Continuous variables
were presented as mean ± standard deviation or median
with interquartile ranges (IQR). Signifcance testing was
carried out using Student’s t test for normally distributed
data and Mann-Whitney U test for non-normal data.
Chi-square test or Fisher exact test was used for categor-
ical variables. Risk factors for three-month treatment
outcomes of CM or TBM were identified using a logistic
regression model. All variables were initially tested by
univariate analysis and those with a P < 0.05 were
entered stepwise into multivariate analysis by using the
forward conditional method. Then the regression equa-
tions for predicting the probability of poor prognosis of
CM or TBM were established. Receiver operating char-
acteristic (ROC) curves were plotted for these two
predicted models with the Medcalc software version
11.5.1.0 (Medcalc software bvba, Belgium). Predictive
accuracy was assessed by calculating the areas under the
ROC curves (AUC). An AUC of > 0.8 was considered




From January 2008 to December 2015, a total of 126
CM patients and 105 TBM patients without HIV infec-
tion were included in this retrospective study. The
clinical characteristics of these patients were shown in
Table 1. There was no significant difference between
CM and TBM patients in gender.
Most patients with CM were from 30 to 60 years (65/
126, 51.6%), but most of TBM patients were aged under 30
years (54/105, 51.4%). Among CM patients, the most com-
mon initial symptoms were headache (118/126, 96.7%),
followed by fever (71/126, 56.3%), vomiting (71/126, 56.3%)
and altered mentation (51/126, 40.5%). The most common
presenting symptoms of TBM patients were also headache
(87/105, 82.9%), fever (72/105, 68.6%) and vomiting (47/
105, 44.8%). CM patients were more likely to present with
headache, abnormal vision and hearing, and less likely to
present with fever and cough than TBM patients (P < 0.05).
The most frequently underlying diseases, factors or
complications of CM patients were corticosteroid use (22/
126, 17.5%), pulmonary infection (22/126, 17.5%), hepato-
biliary diseases (15/126, 11.9%) and diabetes mellitus (13/
126, 10.3%). However, tuberculosis outside CNS was the
most common in TBM patients, especially disseminated
tuberculosis (27/62, 43.5%, data not shown). Twenty
percent of patients had no underlying condition.
Laboratory data and radiological findings
Laboratory data and radiographic findings are prior to
shown in Table 2. The CSF WBC and total protein in CM
patients were lower than those of TBM group (P < 0.05).
There was no statistical difference in CSF glucose, chlor-
ide level and opening pressure in LP between the two
groups. In HIV negative CM group, CD4/CD8 ratio in
serum was significantly decreased compared to the TBM
group.
Brain MRI was performed in 84.9% (107/126) patients
with CM and 76.2% (80/105) patients with TBM. Other
patients were examined by head CT. The most common
manifestations were cerebral ischemia, demyelination,
meningeal enhancement and encephalitis in these two
groups. A total of 15.9% (20/126) patients in CM group
and 11.4% (12/105) in TBM group had normal image
findings. A higher percentage of CM patients presented
with cerebral ischemia/infarction and demyelination
than TBM patients (P < 0.05), but encephalitis and
cerebral edema were more common in TBM patients
(P < 0.05).
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CM and TBM specific test results are shown in Table 3.
For CM patients, latex agglutination CrAg titer were posi-
tive in 99.2% (125/126) of them. The positive rates of CSF
India ink stain and CSF culture for C. neoformans in CM
patients were 77.8% (98/126) and 79.3% (100/126),
respectively. IGRA had higher positive rate than other
detection methods in TBM patients (P < 0.05).
Treatment outcome
A total of 38.1 and 53.3% of patients with CM and TBM
received treatment within 30 days after the onset of
clinical symptoms, respectively. And the proportion of
patients with a duration of more than 2 month was higher
in the CM group than TBM group (26.6% vs. 15.2%,
P = 0.100), but there was no significant difference.
After three months of treatment, 63.5% (80/126) of
CM patients and 77.1% (81/105) of TBM patients had
improved (P = 0.031).
Risk factors for poor treatment outcome of HIV negative
CM and TBM patients
Univariate analysis revealed that the factors impacting
the prognosis of CM patients were age, altered menta-
tion, demyelination, CD4/CD8 ratios < 1 and CSF
CrAg ≥ 1:1024. Multivariate analysis showed that age, al-
tered mentation, CD4/CD8 ratios < 1 and CSF CrAg ≥
1:1024 were independent risk factors for poor prognosis.
For TBM patiens, multiple regression analysis showed
that hydrocephalus (OR = 7.290, 95% CI: 1.630–32.606,
P =0.009) and no less than three underlying diseases
(OR = 6.899, 95% CI: 1.766–26.949, P = 0.005) were the
risk factors, and headache was a protective factor of
prognosis, as shown in Table 4.
ROC curve for the prognostic index derived from the
logistic regression models
Prediction models for the probability of poor prognosis
in patients with CM and TBM are shown in Appendix 1.
The ROC curves of the models of CM and TBM are
shown in Additional file 1: Figure S1.
Discussion
Many patients with CM and TBM were misdiagnosed or
had a delay in diagnosis. Fever, headache, vomiting,
altered mentation and meningeal irritation were the
most common initial symptoms of both CM and TBM
patients. However, CM patients were more likely to
suffer headache, vision and hearing damage, TBM
patients were more prone to have fever and cough.
These results were fairly consistent with previous reports
[9, 17, 18]. One review showed headache (87%), fever
(74%), meningeal irritation (67%), vomiting (61%) and al-
tered mentation (26%) as the most common clinical
manifestations of CM [9]. One study showed that among
Table 1 Demographic and clinical features in HIV negative
patients with cryptococcal meningitis (CM) and tuberculous
meningitis (TBM)
Variables CM (N=126) TBM (N=105) P-value
Sex
Male 79(62.7%) 57(54.3%) 0.227
Female 47(37.3%) 48(45.7%)
Age (years)
≤30 29(23.0%) 54(51.4%) <0.001
31–60 65(51.6%) 35(33.3%)
>60 32(25.4%) 16(15.2%)
Presenting symptoms and signs
Headache 118(96.7%) 87(82.9%) 0.012
Fever 71(56.3%) 72(68.6%) 0.038
Vomiting 71(56.3%) 47(44.8%) 0.263
Altered mentation 51(40.5%) 43(41.0%) 0.524
Abnormal vision 35(27.8%) 12(11.4%) 0.002
Cough 7(5.6%) 24(22.9%) <0.001
Seizure 14(11.1%) 6(5.7%) 0.111
Abnormal hearing 14(11.1%) 3(2.9%) 0.014
Apopsychia 6(4.8%) 2(1.9%) 0.208
Dyspnea 5(4.0%) 1(1.0%) 0.155
Meningeal signs 89(70.6%) 68(64.8%) 0.209
Pathological signs 22(17.5%) 23(21.9%) 0.247
Underlying diseases, factors or complications
Corticosteroid medication 22(17.5%) 6(5.7%) 0.005
Pnumonary infection 22(17.5%) 13(12.4%) 0.188
Hepatobiliary diseases 15(11.9%) 12(11.4%) 0.539
Tuberculosis outside CNS 12(9.5%) 62(59.0%) <0.001
Immune system disease 11(8.7%) 6(5.7%) 0.269
Hypertension 11(8.7%) 3(2.9%) 0.054
Diabetes mellitus 13(10.3%) 10(9.5%) 0.510




Renal transplantation 4(3.2%) 2(1.9%) 0.431
Hematology disease 3(2.4%) 1(1.0%) 0.382
Others 13(10.2%) 12(11.4%) 0.571
None 29(23.0%) 20(19.0%) 0.284
Time from onset of symptoms to treatment (d)




Outcome Improved 80(63.5%) 81(77.1%) 0.031
Worse/Died 46(36.5%) 24(22.9%)
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patients without HIV, those with CM were more likely
to present headache, altered mentation, vision and hear-
ing damage as compared to those with TBM [18].
Although CM and TBM are often considered as an
opportunistic infection in patients with HIV, they are
also seen in individuals with apparently normal immune
function. In this study, corticosteroid medication, hepa-
tobiliary diseases (abnormal liver function for various
reasons, such as chronic hepatitis, cirrhosis) and dia-
betes mellitus occupied the top three underlying
diseases and factors for CM patients. A study reviewed
3698 cryptococcosis cases that found the most common
underlying diseases were HIV infection, tuberculosis,
liver disease, systemic lupus erythematosus and diabetes
mellitus, while 17% had no underlying diseases [9]. An-
other study showed the commom underlying disease of
HIV negative CM patients were hepatobiliary diseases,
hypertension, cancer and diabetes mellitus [7]. Sixty-two
TBM patients, 27 of them were disseminated tubercu-
losis, in this study were known to have pulmonary
Table 3 The positive rate of pathogens and other serological tests for diagnosis of cryptococcal meningitis (CM) and tuberculous
meningitis (TBM) in HIV negative patients
Variables CM (N=126) Variables TBM (N=105)
India ink stain 98 (77.8%) TB smearing 5 (4.8%)
CSF fungal culture 100 (79.3%) TB DNA 59 (56.2%)
India ink stain & fungal culture 72 (57.1%) Mycobacterium tuberculosis culture 9 (8.6%)
CrAg 125 (99.2%) IGRA 94 (89.5%)
CrAg titer ≥1:1024 73 (57.9%) TST 62 (60.0%)
CSF cerebrospinal fluid, CrAg cryptococcal antigen, TST tuberculin skin test, IGRA interferon gamma release assay
Table 2 Laboratory data and radiographic findings in HIV negative patients with cryptococcal meningitis (CM) and tuberculous
meningitis (TBM)
Variables CM (N=126) TBM (N=105) P-value
CSF
WBC (cells/mm3), Median (IQR) 80.00 (20.00–200.00) 120.00 (59.00–295.00) 0.005
Total protein (mg/dL), Median (IQR) 0.83 (0.58–1.32) 1.53(0.99–2.66) <0.001
Glucose (mmol/L), Median (IQR) 1.57 (0.80–2.56) 1.78(1.10–2.35) 0.694
Chloride (mmol/L), (mean±SD) 118.11±6.67 111.40±7.59 0.169
Open pressure > 220mm H2O 98 (77.78%) 75 (71.4%) 0.289
Serum
Albumin(g/L), (mean±SD) 37.77±5.29 36.61±5.20 0.688
WBC (×109/L), (mean±SD) 8.89±3.51 7.46±3.45 0.701
Neutrophile (%) 78.44±10.85 75.92±11.33 0.690
Hemoglobin (g/L), (mean±SD) 122.83±23.05 118.50±22.71 0.548
CD3+ T lymphocyte (%) 65.11±14.25 70.96±13.20 0.533
CD4+ T lymphocyte (%) 28.71±10.46 34.77±11.27 0.542
CD8+ T lymphocyte (%) 25.40±8.57 25.19±10.26 0.139
CD4/CD8 ratio 1.22±0.59 1.71±1.12 0.003
Brain images (CT/MRI)
Cerebral ischemia/infarction 55 (43.7%) 30 (28.6%) 0.028
Demyelination 30 (23.8%) 14 (9.5%) 0.046
Meningeal enhancement 23 (18.3%) 20 (16.0%) 0.877
Hydrocephalus 16 (12.7%) 17(16.2%) 0.709
Encephalitis 14 (11.1%) 40 (38.1%) <0.001
Cerebral edema 4 (3.17%) 13 (12.4%) 0.010
Others 4 (3.17%) 8 (7.6%) 0.147
Normal 20 (15.9%) 12 (11.4%) 0.347
CSF cerebrospinal fluid, WBC white blood count, MRI magnetic resonance imaging
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tuberculosis. Gu et al. also found 30.1% of TBM patients
derived their TBM from disseminated tuberculosis [17].
TBM is the most severe form of extrapulmonary tuber-
culosis, it can occur in isolation or along with a pulmon-
ary focus. TBM and disseminated tuberculosis are
usually due to hematogenous dissemination of the
tubercle bacillus [19].
In CM and TBM patients, the most common manifes-
tations on brain imagines were cerebral ischemia/infarc-
tion, meningeal enhancement, hydrocephalus, which
consistent with previous reports [3, 5, 20]. Demyelin-
ation were seen on some patients’ head MRI or CT. Of
course, MR imaging is more sensitive in depicting
demyelination than head CT. In this study, demyelin-
ation was more commom for CM patients than in prior
reports [5, 20]. Another study showed that gadolinium-
enhancing white matter lesions found on brain MRI of
CM patients. Biopsy revealed the lesions of resembled
demyelinating were cryptococci, non-specific inflamma-
tory changes or small perivascular lymphocyte collec-
tions. Which possibly be leukoencephalopathy or
immune response to the pathogen [21]. In addition, our
patients showed evidence of cerebral ischemia or en-
cephalitis more often than previous studies [9, 18], this
was likely related to the increased sensitivity of MRI
with diffusion-weighted imaging.
Patients with TBM presented with higher CSF WBC
and total protein than CM patients, similar to prior
studies [18]. A low ratio of CD4/CD8 was also found in
the apparently healthy CM patients, it’s possible those
patients may have some undetectable underlying disease.
In our study, multivariate analysis showed that age >60
years, altered mentation, CD4/CD8 ratios < 1 and CSF
CrAg ≥ 1:1024 were closely correlated with poor outcome
of CM patients. Previous studies showed there were many
poor prognostic factors for CM, including Cryptococcus
growth from sites other than CSF, altered mentation,
intracranial pressure (ICP) >400 mmH2O, CSF glucose < 40
mg/dl, high CSF CrAg titer, decreased CSF/blood glucose
ratio, papilledema, chronic use of corticosteroids or other
immunosuppressants, absence of headache and low GCS
score [7, 20, 22–24]. Our study showed that CrAg test was
highly specific to the diagnosis of cryptococcal meningitis,
and it also had prognostic value, similar to previous studies
[25]. Though middle-aged people made up a greater per-
centage of our CM patients, mortality was increased with
patients aged greater than than 60 years, possibly related to
a decreased immune response to pathogens declines with
age [26].
For TBM patients, poor outcome was related to
hydrocephalus and more than three underlying diseases
in the present study. Hydrocephalus, optochiasmatic ara-
chnoiditis, microbiologically confirmed TBM have been
associated with poor outcome of TBM in previous stud-
ies [27, 28]. Early diagnosis and treatment improve prog-
nosis. We found no literature showing that more than
three underlying diseases was correlated with poor out-
come of TBM. It might be because these studies did not
include this factor. On admission, there were 17.1%
TBM patients had no headache. Headache was a pro-
tective factor for TBM in this study. The inflammation
that occurs in the subarachnoid space during meningitis
can largely be attributed to the response of the immune
system to bacteria, which leads to headache [29].
Patients without headache probably means they have
weak immune response. So they had poor outcome.
There were some limitations concerning this study.
Because our study was a retrospective research, the
medical records about epidemiological contact history
were incomplete, so we did not analyse relevant
Table 4 Risk factors associated with poor prognosis of HIV negative cryptococcal meningitis (CM) and tuberculous meningitis (TBM)
patients
Cryptococcal meningitis (CM)
Variables Univariate analysis Multivariate analysis
Odds ratio 95% CI P-value Odds ratio 95% CI P-value
Ages>60y 5.946 2.493–14.183 <0.001 4.981 1.955–12.692 0.001
Altered mentation 4.533 1.763–11.656 0.002 5.054 1.592–16.046 0.006
Demyelination 7.270 2.560–20.646 <0.001
CD4/CD8 ratio<1 8.475 2.831–25.378 <0.001 8.782 2.436–31.661 0.001
CrAg titer ≥1:1024 5.338 1.769–16.103 0.003 4.853 1.377–17.098 0.014
Tuberculous meningitis (TBM)
Fever 9.659 1.208–77.252 0.033
Headache 0.139 0.042–0. 459 0.001 0.125 0.032–0.497 0.003
Hydrocephalus 3.692 1.062–12.839 0.040 7.290 1.630–32.606 0.009
Underlying diseases or factors≥3 6.817 1.927–19.869 0.002 6.899 1.766–26.949 0.005
HIV human immunodeficiency virus, CrAg cryptococcal antigen, CI confidential intervals
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contents. In addition, there were three patients with CM
using voriconazole because they could not tolerate the
adverse effect of amphotericin B or they complicated
renal disease. But just three patients used non standard
treatments, which might not affect the statistic results.
Conclusions
We found that compared to patients with TBM, CM
patients were more likely to present with headache,
vision and hearing damage, cerebral ischemia and de-
myelination. TBM patients were more likely to have
fever, cough, encephalitis and cerebral edema. CM pa-
tients had lower CSF WBC, total protein, and CD4/
CD8 ratio than those of TBM patients. Prognosis was
poorer for CM patients than TBM patients. Age, al-
tered mentation, CD4/CD8 ratios < 1 and CSF CrAg ≥
1:1024 were independent risk factors for poor progno-
sis of HIV negative CM patients. Hydrocephalus and
no less than three underlying diseases were the risk
factors, and headache was a protective factor for HIV
negative patients with TBM. Our prediction models
may be helpful for making treatment plan and prog-
nosis assessment. Of course, specific identification of
the offending microorganism is considered to be the
gold standard in diagnosing infectious diseases. More
work needs to be done to develop more rapid, sensi-
tive and specific diagnosis methods and more effective
treatments for patients CM and TBM, and the prog-
nosis can be improved accordingly.
Appendix 1
Prediction models for the probability of poor prognosis
in patients with cryptococcal meningitis (CM) and
tuberculous meningitis (TBM)
Prediction model for the probability of poor prognosis
in CM: PCM=e
x/(1 + ex), x = −6.360 + (1.606 × age) +
(1.620 × altered mentation) + (2.173 × CD4/CD8 ratios)
+ (1.579 × CSF CrAg titer). Prediction model for the
probability of poor prognosis in TBM: PTBM=e
x/(1 + ex),
x = −0.658 + (1.931 × underlying diseases) + (1.987 ×
hydrocephalus) + (−2.079 × headache). Where the fol-
lowing are used: e is the natural logarithm; age>60y, al-
tered mentation, CD4/CD8 ratios<1, CSF CrAg titer
≥1:1024, underlying diseases≥3 and headache are scored
as 1 or otherwise as 0; hydrocephalus was derived from
the imaging report (1: yes, 0: no). The ROC curves of
the risk index models for predicting poor prognosis of
CM or TBM are shown in Additional file 1: Figure S1.
The AUC of CM was 0.872 (95% CI: 0.786–0.932). The
appropriate cut off point was selected at PCM=0.5127,
and the model achieved a sensitivity of 69.44%, a specifi-
city of 91.23%. The AUC of TBM was 0.802 (95% CI:
0.700–0.882), the appropriate cut off point was 0.3209
for PTBM with a sensitivity of 57.89% and a specificity of
88.89%.
Additional file
Additional file 1: Figure S1. Prediction models for the probability of
poor prognosis in patients with cryptococcal meningitis and tuberculous
meningitis. Receiver operator characteristic (ROC) curve for the
prognostic index derived from the logistic regression models of
cryptococcal meningitis and tuberculous meningitis. For cryptococcal
meningitis patients, area under the ROC curve = 0.872 (95% CI:
0.786–0.932), for tubercular meningitis patients, area under the ROC
curve = 0.802 (95% CI: 0.700–0.882). (TIF 3370 kb)
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